Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407S6 | ISIN: US60855D3098 | Ticker-Symbol: MOL
Lang & Schwarz
18.09.25 | 07:00
0,510 Euro
-100,00 % -0,510
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULIN BIOTECH INC Chart 1 Jahr
5-Tage-Chart
MOLECULIN BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5000,52007:00

Aktuelle News zur MOLECULIN BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.09.Moleculin Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
10.09.H.C. Wainwright bestätigt Kaufempfehlung für Moleculin Biotech mit Kursziel 4,00 US-Dollar4
10.09.H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock1
09.09.Moleculin expands AML trial sites globally, targets 45 patients by Q43
09.09.Moleculin erweitert globale AML-Studie und peilt Rekrutierung von 45 Patienten bis Q4 2025 an-
09.09.Moleculin Biotech, Inc.: Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial1
08.09.Moleculin Biotech, Inc.: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia63Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,...
► Artikel lesen
08.09.Moleculin Biotech, Inc. - 8-K, Current Report1
MOLECULIN BIOTECH Aktie jetzt für 0€ handeln
28.08.Moleculin Biotech, Inc.: Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds4
27.08.Moleculin Biotech, Inc.: Moleculin Issues New Positive AML Overall Survival Data150Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L-7L)...
► Artikel lesen
27.08.Moleculin Biotech, Inc. - 8-K, Current Report1
13.08.Moleculin Biotech, Inc.: Moleculin Reports Second Quarter 2025 Financial Results and Highlights512- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated...
► Artikel lesen
13.08.Moleculin Biotech, Inc. - 8-K, Current Report-
12.08.Moleculin Biotech, Inc. - 10-Q, Quarterly Report1
06.08.Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment148Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in...
► Artikel lesen
06.08.Moleculin Biotech, Inc. - 8-K, Current Report-
30.07.Moleculin receives European patent notice for cancer drug Annamycin2
30.07.Moleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin567- New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company...
► Artikel lesen
30.07.Moleculin Biotech, Inc. - 8-K, Current Report1
17.07.Moleculin Biotech, Inc.: Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships3
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1